Market Introduction
The United Arab Emirates (UAE), Saudi Arabia and South Africa are the 3 major countries in the MEA. The Saudi Arabia was the largest market for Plasma fractionation in this region in 2021. The market for plasma fractionation in the MEA is anticipated to grow at a CAGR 5.2% during the forecast period; this growth is attributed to the rising prevalence of various diseases and increasing government initiatives in the region.
Economic uncertainties and ongoing conflicts are worsening the condition in the region. For instance, countries such as Syria, Libya, and Yemen are suffering violent conflicts and cannot implement robust public health measures. Iran was in a deep economic recession due to the US sanctions. Also, the major source of economic stabilization in the Middle East countries is oil production and export. However, the COVID-19 pandemic is causing turbulence in the economies of the Middle East. A sudden drop in domestic and external demand for goods and products, especially crude oil, and halted production due to labor shortage are major impacts observed in the region. The spread of COVID-19 in the region caused heavy burdens on healthcare professionals. Cardiac surgeons were overloaded with emergency cardiac surgeries, management of COVID-19 patients, and implementation of safety guidelines to prevent the spread of the virus. The rapid spread of the virus impacted elective surgeries. Hence, the COVID-19 outbreak negatively impacted the growth of the MEA plasma fractionation market.
The plasma fractionation market in the MEA is expected to grow from US$ 2,455.61 million in 2021 to US$ 3,490.73 million by 2028; it is estimated to grow at a CAGR of 5.2% from 2021 to 2028. Blood plasma is among the emerging method for treating various chronic diseases. The plasma consists of essential components, such as proteins, albumin, globulins, fibrinogen, clotting factors and inhibitors, and others. It is widely used in blood cancer, COVID19, Atrial fibrillation, leukemia, and others. The plasma is separated from the donated blood by using plasma Fractionation. The regulatory agencies are also providing the required approvals for the use of plasma in treatment processes. Thus, active involvement and approval by the regulatory and government are expected to encourage the application of blood plasma. The blood plasma can be stored for up to one year by freezing within 24 hours of blood donated to protect the valuable clotting factors and can be used post thawing process. Many blood bank settings are established in every country, have access to healthcare service providers, and are funded by various governments and other organizations. Therefore, as per the above-stated factors, the blood plasma fractionation related market in the forecast period.
Key Market Segments
MEA plasma fractionation market is segmented into product, application, end user, and country. The MEA plasma fractionation market, based on product, has been segmented into immunoglobulin, albumin, coagulation factor concentrates, protease inhibitors, and others. The immunoglobulin segment is likely to hold the largest share of the market in 2021. The MEA plasma fractionation market, based on application is segmented into neurology, immunology, hematology, critical care, pulmonology, and others. In 2021, the Neurology segment is likely to hold the largest share of the market. The MEA plasma fractionation market, based on end user is segmented into hospitals and clinics, clinical research laboratories, academic institutes. In 2021, the hospitals and clinics segment is likely to hold the largest share of the market. Based on country, the MEA plasma fractionation market is segmented into Saudi Arabia, South Africa, the UAE, and rest of the MEA. Rest of the MEA held the largest market share in 2021.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the plasma fractionation market in MEA are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Bharat Serums and Vaccines Limited (BSV); Bio Products Laboratory Ltd.; Biotest AG; CSL Limited; Grifols, S.A.; Kedrion S.p.A; Octapharma AG; and SK Plasma.
Reasons to buy report
- To understand the MEA plasma fractionation market landscape and identify market segments that are most likely to guarantee a strong return.
- Stay ahead of the race by comprehending the ever-changing competitive landscape for MEA plasma fractionation market.
- Efficiently plan M&A and partnership deals in MEA plasma fractionation market by identifying market segments with the most promising probable sales.
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form MEA plasma fractionation market.
- Obtain market revenue forecast for market by various segments from 2021-2028 in MEA region.
MEA Plasma Fractionation Market Segmentation
MEA Plasma Fractionation Market - By Product
-
Immunoglobulin
- Intravenous Immunoglobulin (IVIG)
- Subcutaneous Immunoglobulin (SCIG)
- Albumin
- Coagulation Factor Concentrates
- Protease Inhibitors
- Other
MEA Plasma Fractionation Market - By Application
- Neurology
- Immunology
- Hematology
- Critical Care
- Pulmonology
- Others
MEA Plasma Fractionation Market - By End User
- Hospitals and Clinics
- Clinical Research Laboratories
- Academic Institutes
MEA Plasma Fractionation Market - By Country
- Saudi Arabia
- South Africa
- UAE
- Rest of the MEA
MEA Plasma Fractionation Market - Company Profiles
- Bharat Serums and Vaccines Limited (BSV)
- Bio Products Laboratory Ltd.
- Biotest AG.
- CSL Limited
- Grifols, S.A.
- Kedrion S.p.A
- Octapharma AG
- SK Plasma
Middle East and Africa Plasma Fractionation Market Strategic Insights
Middle East and Africa Plasma FractionationMarket Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 2,455.61 Million |
| Market Size by 2028 | US$ 3,490.73 Million |
| CAGR (2021 - 2028) | 5.2% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product
|
|
Regions and Countries Covered
|
|
| Middle East and Africa | South Africa, Saudi Arabia, UAE, Rest of Middle East and Africa |
| Market leaders and key company profiles |
|
Middle East and Africa Plasma Fractionation Market Country and Regional Insights